AbbVie (ABBV) — Company Research

Last Updated: 17 Oct 2026

AbbVie (NYSE: ABBV) is a US biopharmaceutical group whose sales are led by the immunology drugs Skyrizi and Rinvoq, a fast-growing neuroscience franchise (Vraylar, Botox Therapeutic, the migraine drugs and the newly approved Parkinson’s drug JUVMO), oncology and the Allergan aesthetics business. The 2026 story is whether Skyrizi and Rinvoq can keep more than replacing lost Humira sales while AbbVie absorbs IRA price setting, a heavier debt load after the $10.9bn Apogee deal and recurring in-process R&D charges. This refreshed report covers results through Q2 2026, the balance sheet at 30 Jun 2026, valuation and risks, using company releases and SEC filings only.

1. Company Snapshot

Field	Value
Ticker / Exchange	ABBV / NYSE
Headquarters	1 North Waukegan Road, North Chicago, Illinois, USA
CEO / Leadership	Robert A. Michael, Chairman & CEO; Scott T. Reents, EVP & CFO
Sector	Healthcare — biopharmaceuticals and medical aesthetics
Employees	~57,000 in more than 70 countries at 31 Dec 2025 (FY2025 10-K)
Market cap	~$504.4bn ($285.42 at 16 Oct 2026 close × ~1.767bn shares at 27 Jul 2026)
FY2025 Revenue	$61,160m net revenues (+8.6%)
FY2025 GAAP net income	$4,226m ($2.36 per diluted share)
FY2025 adjusted EPS	$10.00 (after a −$2.76 per share IPR&D and milestones impact)
2026 guidance	Adjusted EPS $13.76–$13.96 (lowered on 05 Oct 2026 for $216m of Q3 IPR&D; started the year at $14.37–$14.57)
Dividend	$1.73 per quarter ($6.92 annualised; yield ~2.4%)

2. Bull & Bear Case

Bull Case

• Skyrizi and Rinvoq still compounding: Q2 2026 Skyrizi sales were $5,505m (+24.4%) and Rinvoq $2,525m (+24.5%), lifting Immunology to $8,786m (+15.1%) even as Humira fell 35.9%.
• Long patent runway: US composition-of-matter patents on Skyrizi and Rinvoq run to 2033, and generic settlements mean no US Rinvoq generic before Apr 2037 (FY2025 10-K).
• Neuroscience is a second engine: Neuroscience revenue rose 20.3% to $3,228m in Q2 2026, and the FDA approved JUVMO (tavapadon) for Parkinson’s disease on 28 Sep 2026.
• Cash generation covers the dividend: Trailing-twelve-month free cash flow to 30 Jun 2026 was about $18.2bn against an annual dividend bill of about $12.2bn, and the quarterly payout was raised 5.5% to $1.73 from Feb 2026.
• Deep late-stage pipeline: Temab-A won two FDA Breakthrough Therapy Designations on 07 Oct 2026, etentamig and epcoritamab both hit Phase 3 endpoints in Sep–Oct 2026, and the Apogee deal added IL-13 antibody zumilokibart.

Bear Case

• Debt and negative equity: Total debt was about $70.8bn at 30 Jun 2026 before about $10bn of new notes issued in Aug 2026 for Apogee, and stockholders’ equity was −$5.9bn.
• Erosion and price setting: Humira (−35.9%) and Imbruvica (−29.4%) are still shrinking, Imbruvica has carried a Medicare negotiated price since 01 Jan 2026, and Vraylar, Linzess (2027) and Botox (2028) follow.
• Two-drug concentration: Skyrizi and Rinvoq made up about 47% of Q2 2026 net revenues, so any safety, competitive or pricing setback in immunology would weigh on the whole group.
• IPR&D charges keep cutting guidance: Year-to-date IPR&D reached $1,251m by 05 Oct 2026, and the 2026 adjusted EPS guidance midpoint has fallen from $14.47 in February to $13.86 as those charges were added.
• Aesthetics and oncology lagging: Aesthetics revenue fell 6.1% in FY2025 and was flat (+0.3%) in Q2 2026, while Oncology fell 1.5% in Q2 2026.

3. Business Segments

AbbVie reports one global business segment. Revenue is disclosed by therapeutic area and key product. Percentages use FY2025 net revenues of $61,160m from the Q4 2025 earnings release. From 2026 the product tables no longer show a separate Eye Care line.

Segment / category	% of revenue	What it is
Immunology	49.7% ($30,406m)	Skyrizi ($17,562m), Rinvoq ($8,304m) and Humira ($4,540m, −49.5%) for psoriasis, arthritis and inflammatory bowel disease.
Neuroscience	17.6% ($10,767m)	Vraylar, Botox Therapeutic, Ubrelvy and Qulipta for migraine, Vyalev for Parkinson’s disease.
Oncology	10.9% ($6,655m)	Venclexta, Imbruvica, Elahere, Epkinly and Emrelis in blood cancers and solid tumours.
Aesthetics	7.9% ($4,860m)	Botox Cosmetic, Juvederm fillers and other Allergan Aesthetics products.
Other key products	6.1% ($3,736m)	Mavyret (hepatitis C), Creon (pancreatic enzymes) and Linzess (gastrointestinal).
Eye Care	3.4% ($2,109m)	Alphagan, Combigan and other ophthalmic drugs; no longer shown as a separate line from 2026.
All other	4.3% (~$2,627m)	Remaining products not listed in the key-product tables (derived from disclosed totals).

4. Business Model & Moat

How it makes money. AbbVie discovers, licenses and acquires patented medicines and aesthetic products and sells them to wholesalers, pharmacies, hospitals and clinics worldwide, with the US the largest market. The adjusted gross margin was 84.7% and the adjusted operating margin 48.3% in Q2 2026, which funds R&D, business development and a dividend of $6.92 per share a year.

Replacing Humira by design. AbbVie built Skyrizi and Rinvoq to take over from Humira, which now faces US biosimilar competition. FY2025 Humira sales were $4,540m, while Skyrizi and Rinvoq together reached $25,866m. Acquisitions and licences, most recently Apogee and the Gubra amylin programme, add further growth options.

Moat. Patents and regulatory exclusivity protect pricing on each product until expiry, backed by large-scale biologics manufacturing and an established commercial presence in immunology. The Allergan aesthetics brands add a consumer-facing franchise with no patent cliff, though it is more sensitive to consumer spending.

Policy positioning. In Jan 2026 AbbVie signed a voluntary three-year pricing agreement with the US administration covering Medicaid and TrumpRx pricing. It is paired with a $100bn, 10-year US R&D and capital commitment in return for tariff relief and exemption from future pricing mandates.

5. Financial Health

Annual figures are from AbbVie’s Q4 earnings releases and SEC XBRL filings. Long-term debt is the non-current balance-sheet amount of long-term debt and finance lease obligations at year end.

Fiscal Year	Revenue ($m)	YoY %	GAAP EPS	Adjusted EPS	Dividend/share	Long-term debt (YE)
FY2021	$56,197m	+22.7%	$6.45	$12.70	$5.31	$64,189m
FY2022	$58,054m	+3.3%	$6.63	$13.77	$5.71	$59,135m
FY2023	$54,318m	−6.4%	$2.72	$11.11	$5.99	$52,194m
FY2024	$56,334m	+3.7%	$2.39	$10.12	$6.29	$60,340m
FY2025	$61,160m	+8.6%	$2.36	$10.00	$6.65	$58,941m

Adjusted EPS is as reported in each Q4 release. AbbVie does not exclude acquired IPR&D and milestone charges from adjusted EPS; they cut FY2025 adjusted EPS by $2.76. Dividends are declared per share (SEC XBRL).

Quarterly progression, most recent first, with the FY2025 total in bold:

Quarter / Half	Revenue	Adjusted EPS	GAAP EPS
Q2 2026	$16,990m	$3.65	$2.03
Q1 2026	$15,002m	$2.65	$0.39
Q4 2025	$16,618m	$2.71	$1.02
Q3 2025	$15,776m	$1.86	$0.10
FY2025 total	$61,160m	$10.00	$2.36

IPR&D and milestone charges cut adjusted EPS by $1.50 in Q3 2025, $0.71 in Q4 2025, $0.41 in Q1 2026 and $0.17 in Q2 2026. Over the four quarters to 30 Jun 2026, revenue was about $64,386m, GAAP EPS about $3.54 and adjusted EPS about $10.87.

Cash flow and balance sheet. All figures are from SEC XBRL filings (FY2025 10-K and Q2 2026 10-Q).

• Operating cash flow: $19.03bn in FY2025; ~$19.51bn trailing twelve months to 30 Jun 2026.
• Capital expenditure: $1.21bn in FY2025; ~$1.30bn trailing twelve months.
• Depreciation & amortisation: $8.14bn in FY2025 (depreciation $0.76bn plus intangible amortisation $7.38bn); ~$7.87bn trailing twelve months.
• Debt at 30 Jun 2026: non-current long-term debt and finance leases $62,481m plus current portion $8,341m, about $70.8bn in total. About $10bn of senior notes (2028–2066) followed on 18 Aug 2026 to fund Apogee.
• Cash at 30 Jun 2026: cash and equivalents $6,569m. Stockholders’ equity was −$5,935m.

6. Valuation

Raw metrics, October 2026. Not opinions on whether the stock is cheap or expensive.

Metric	Value
Market cap	~$504.4bn (price $285.42 at 16 Oct 2026 close × ~1.767bn shares)
Enterprise value	~$568.6bn (market cap ~$504.4bn + total debt ~$70.8bn − cash ~$6.6bn per 30 Jun 2026 balance sheet; total debt = non-current $62.48bn + current $8.34bn). Including the Aug 2026 Apogee notes and the ~$10.9bn cash paid in Sep 2026, pro forma EV is roughly $579bn
Trailing P/E (GAAP)	~80.6x ($285.42 / ~$3.54 TTM GAAP EPS, Q3 2025–Q2 2026, depressed by IPR&D charges and intangible amortisation); on TTM adjusted EPS of ~$10.87 the multiple is ~26.3x
P/E (forward)	~20.6x ($285.42 / $13.86, the midpoint of 2026 adjusted EPS guidance of $13.76–$13.96)
P/S (TTM)	~7.8x ($504.4bn / ~$64.39bn TTM revenue)
EV/EBITDA (TTM)	~23.0x (EV ~$568.6bn / EBITDA ~$24.74bn; EBITDA = TTM GAAP operating income $16.87bn + total D&A $7.87bn, using depreciation plus intangible amortisation; operating income is after IPR&D and milestone charges)
P/FCF	~27.7x (market cap ~$504.4bn / TTM FCF ~$18.21bn; FCF = operating CF $19.51bn − capex $1.30bn); on FY2025 FCF of ~$17.82bn ($19.03bn − $1.21bn) it is ~28.3x
Price/book	n/m — stockholders’ equity was negative (−$5.9bn) at 30 Jun 2026
Dividend yield	~2.4% ($6.92 annualised / $285.42)
52-week high	$291.40 (intraday, 15 Oct 2026)
52-week low	$190.75
Short interest (% of float)	~1.0% (~16.3m shares short at 30 Sep 2026 settlement, Yahoo Finance data)
Days to cover	~3.9 days

7. What Are They Building

AbbVie’s pipeline aims to extend immunology beyond Skyrizi and Rinvoq, deepen neuroscience and rebuild oncology around antibody-drug conjugates and bispecifics.

• Immunology label expansion: Skyrizi subcutaneous induction in Crohn’s disease was filed in the US in Apr 2026 (decision expected later in 2026) and in the EU in Aug 2026. US filings for Rinvoq in vitiligo and alopecia areata are pending after EU approvals in Jul 2026.
• Apogee assets: Zumilokibart (APG777), a long-acting IL-13 antibody, reported positive Phase 2 APEX Part B data in atopic dermatitis on 30 Sep 2026. APG273 (IL-13/TSLP) targets asthma.
• Neuroscience: JUVMO (tavapadon) launches in the US in Oct 2026. Atogepant posted positive Phase 3 data in menstrual migraine, and a new Phase 2 of emraclidine is recruiting after the 2024 schizophrenia trials failed.
• Oncology: Temab-A (ABBV-400, a c-Met ADC) is in multiple Phase 3 studies and won Breakthrough designations in colorectal and lung cancer. Etentamig (ABBV-383) succeeded in the Phase 3 CERVINO myeloma trial, and epcoritamab plus R-CHOP met its PFS endpoint in first-line DLBCL.
• Obesity: ABBV-295, a long-acting amylin analogue licensed from Gubra, started a ~360-patient Phase 2 in Aug 2026.
• Aesthetics: The FDA accepted a Botox Cosmetic filing for masseter muscle prominence on 04 Aug 2026. TrenibotE awaits resubmission after an Apr 2026 manufacturing-only complete response letter.

8. Competitive Landscape

AbbVie competes with other global large-cap pharmaceutical groups, and directly with J&J, Lilly, Pfizer and Amgen in immunology. Market caps are mid-Oct 2026 figures. Metrics come from each company’s FY2025 results release.

Peer	Market cap (Oct 2026)	Key 2025 metric
Eli Lilly (LLY)	~$1,120bn	FY2025 revenue ~$65.2bn, +45%, per Lilly Q4 2025 release
Johnson & Johnson (JNJ)	~$610bn	FY2025 sales ~$94.2bn, +6.0%, per J&J Q4 2025 release
Merck & Co. (MRK)	~$358bn	FY2025 sales ~$65.0bn, +1%, per Merck Q4 2025 release
AstraZeneca (AZN)	~$261bn	FY2025 total revenue $58,739m, +8% at constant exchange rates, per AstraZeneca FY2025 results
Amgen (AMGN)	~$235bn	FY2025 revenue ~$36.8bn, +10%, per Amgen Q4 2025 release
Pfizer (PFE)	~$168bn	FY2025 revenue $62,579m, −2%, per Pfizer Q4 2025 release
Bristol Myers Squibb (BMY)	~$122bn	FY2025 revenue $48,194m, roughly flat, per BMS Q4 2025 release

9. Leadership & Insider Activity

Robert A. Michael is Chairman and CEO, and Scott T. Reents is EVP and CFO; no leadership changes were announced between Aug and Oct 2026. Form 4 filings in 2026 show open-market sales by three officers and no open-market purchases. Other filings were annual equity awards (18 Feb 2026), tax-withholding share dispositions on vesting (27 Feb 2026) and director stock awards.

Name	Date	Type	Shares	Price	Value	Plan Type
Nicholas Donoghoe (EVP, Chief Business & Strategy Officer)	14 Aug 2026	Sale (after option exercise)	32,710	$250.00	~$8.18m	Open market; Form 4 indicates not under 10b5-1
David Purdue (SVP, Controller)	04 Mar 2026	Sale	5,230	$233.56	~$1.22m	Open market; plan status not stated
Perry Siatis (EVP, General Counsel)	02 Mar 2026	Sale	18,668	$234.39	~$4.38m	Open market; plan status not stated
Robert A. Michael (Chairman & CEO)	27 Feb 2026	Tax withholding	36,523	$232.08	~$8.48m	Shares withheld on vesting; not an open-market sale
Perry Siatis (EVP, General Counsel)	25 Feb 2026	Sale (after option exercise)	22,381	$230.00	~$5.15m	Open market; plan status not stated

10. Key Risks

• Humira and Imbruvica erosion (Commercial): Humira sales fell 49.5% in FY2025 and 35.9% in Q2 2026, and Imbruvica fell 29.4% in Q2 2026 under its first Medicare negotiated price.
• US drug pricing (Regulatory): IRA prices apply to Imbruvica from 2026, to Vraylar and Linzess from 01 Jan 2027 and to Botox from 01 Jan 2028, and more products could be selected. The voluntary pricing agreement and the 340B Rebate Model Pilot add further price concessions.
• Leverage (Financial): Total debt of about $70.8bn at 30 Jun 2026, plus about $10bn of Apogee notes, against negative stockholders’ equity. Apogee is guided to dilute EPS by $0.14 in 2026 and $0.46 in 2027.
• Immunology concentration (Commercial): Skyrizi and Rinvoq made up about 47% of Q2 2026 revenue, so new competing immunology drugs, safety label changes or price pressure on either brand would hit the core of the business.
• IPR&D volatility (Financial): Acquired IPR&D and milestone payments are not excluded from adjusted EPS, so licensing deals repeatedly reduce guidance ($1,251m year to date by 05 Oct 2026).
• Litigation (Legal): Humira antitrust claims (trimmed on 01 Oct 2026 but not dismissed), Niaspan antitrust, the Allergan Biocell breast-implant suits and AndroGel post-trial matters remain open.
• Pipeline execution (Operational): Emraclidine’s Phase 2 failure led to a $3.5bn impairment, and the confirmatory Emrelis lung-cancer trial is reported to have slipped to Dec 2028.

11. Recent Developments

• 15 Oct 2026 — Record high. The shares hit an intraday high of $291.40, up from $259.93 on 01 Oct, and closed at $285.42 on 16 Oct. 15 Oct was also the ex-dividend and record date for the $1.73 dividend.
• 13 Oct 2026 — IBD data at ACG. AbbVie presented Skyrizi and Rinvoq inflammatory bowel disease data, including the Phase 3 AFFIRM study of Skyrizi subcutaneous induction.
• 07 Oct 2026 — Two Breakthrough designations for Temab-A. The FDA granted Breakthrough Therapy Designation in third-line-plus colorectal cancer with bevacizumab and in second-line-plus c-Met-positive, EGFR-wildtype NSCLC.
• 05 Oct 2026 — Guidance trimmed for IPR&D. 2026 adjusted EPS guidance moved to $13.76–$13.96 (from $13.87–$14.07) for $216m of Q3 IPR&D. The same day, epcoritamab plus R-CHOP met its PFS endpoint in the Phase 3 EPCORE DLBCL-2 trial.
• 02 Oct 2026 — 340B pilot. AbbVie joined the federal 340B Rebate Model Pilot.
• 01 Oct 2026 — Q3 date and Humira suit. AbbVie set its Q3 2026 results for 30 Oct. A judge dismissed all but one claim in the Sheet Metal Workers Humira antitrust suit.
• 30 Sep 2026 — Zumilokibart Phase 2 positive. APEX Part B data in atopic dermatitis were presented at EADV, alongside Phase 1 ABBV-295 data at EASD.
• 28 Sep 2026 — FDA approves JUVMO. Tavapadon was approved for Parkinson’s disease, with a US launch expected in Oct 2026.
• 22 Sep 2026 — Rinvoq EU approval in pJIA. The European Commission approved Rinvoq for polyarticular juvenile idiopathic arthritis.
• 10 Sep 2026 — Migraine data and dividend. Atogepant met its Phase 3 endpoints in menstrual migraine, and the board declared a $1.73 quarterly dividend payable 16 Nov 2026.
• 03 Sep 2026 — Apogee closes; CERVINO positive. AbbVie completed the ~$10.9bn Apogee acquisition at $135.11 per share and reported positive Phase 3 CERVINO results for etentamig in relapsed/refractory multiple myeloma.

12. Key Dates

• Expected Oct 2026 — US commercial launch of JUVMO (tavapadon)
• 30 Oct 2026 — Q3 2026 results before the market opens, webcast at 8:00am CT
• 16 Nov 2026 — payment date for the $1.73 quarterly dividend
• Expected late 2026 — FDA decision on Skyrizi subcutaneous induction in Crohn’s disease (guided as later in 2026; exact date not disclosed)
• 01 Jan 2027 — Medicare negotiated prices for Vraylar and Linzess take effect
• 01 Jan 2028 — Medicare negotiated price for Botox takes effect
• TBC — US decisions on Rinvoq in vitiligo and alopecia areata, and on Botox Cosmetic for masseter muscle prominence

AbbVie has announced dividend increases alongside Q3 results in most recent years. Any change will be set out in the 30 Oct release. The date for Q4 2026 results and 2027 guidance has not been announced.

Explore more on ChartsView: Live Charts, the Economic Calendar, and join the discussion on the Forum.

---

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.